SCHEMBL19225308

SCHEMBL19225308

CCc1ncc(Cc2ccc(F)cc2F)s1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPER1 Q99527 1/20 0.41
IDO1 P14902 2/20 0.39
AGXT P21549 2/20 0.39
PTGS2 P35354 1/20 0.36
GAA P10253 1/20 0.35
MAPK14 Q16539 2/20 0.35
MPO P05164 1/20 0.34
F2RL3 Q96RI0 1/20 0.34
MAOB P27338 1/20 0.33
QPCT Q16769 1/20 0.33
QPCTL Q9NXS2 1/20 0.33
SLC5A2 P31639 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
SLC6A4 P31645 1/20 0.33
RIPK1 Q13546 2/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19225188 0.88 SLC5A2 (0.42) GPER1IDO1AGXTPTGS2GAA
SCHEMBL16016314 0.82 GPER1 (0.43) GPER1IDO1AGXTPTGS2GAA
SCHEMBL20724148 0.80 STIM1 (0.33) GAA
SCHEMBL12510269 0.79 EPHX2 (0.46) GPER1IDO1AGXTPTGS2MPO
SCHEMBL29442852 0.79 EPHX2 (0.46) GPER1IDO1AGXTPTGS2MPO
SCHEMBL19225206 0.78 SMN1; SMN2 (0.47) GPER1GAAKDM4E
SCHEMBL16018762 0.78 GPER1 (0.41) GPER1IDO1AGXTPTGS2GAA
SCHEMBL19157898 0.77 IDO1 (0.42) IDO1AGXTMAPK14MPOQPCT
SCHEMBL16016321 0.76 IDO1 (0.41) IDO1AGXTPTGS2GAAMAPK14
SCHEMBL19158672 0.75 GPER1 (0.37) GPER1IDO1AGXTPTGS2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202404-B2 Polycyclic pyridone derivative having integrase inhibitory activity SHIONOGI & CO., LTD. (JP) 2019-02-12 US disclosed
US-10011613-B2 Polycyclic pyridone derivative having integrase inhibitory activity SHIONOGI & CO., LTD. (JP) 2018-07-03 US disclosed
US-20170226128-A1 POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2017-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011613-B2 Polycyclic pyridone derivative having integrase inhibitory activity TYMP, CDK6, IMPA1 GPER1 2741/4885IDO1 138/4885AGXT 2646/4885
US-20170226128-A1 POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY TYMP, CDK6, IMPA1 GPER1 2741/4885IDO1 138/4885AGXT 2646/4885
US-10202404-B2 Polycyclic pyridone derivative having integrase inhibitory activity TYMP, CDK6, IMPA1 GPER1 2741/4885IDO1 138/4885AGXT 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.